Prodromidou Anastasia, Frountzas Maximos, Vlachos Dimitrios-Efthymios G, Vlachos Georgios D, Bakoyiannis Ioannis, Perrea Despina, Pergialiotis Vasilios
Laboratory of Experimental Surgery and Surgical Research N.S. Christeas, Athens Kapodistrian University, Greece.
Plast Surg (Oakv). 2015 Winter;23(4):260-4. doi: 10.4172/plastic-surgery.1000934.
Botulinum toxin injections have been investigated for the treatment or prevention of hypertrophic scars in several clinical studies. However, its clinical effectiveness has not yet been established.
To examine all available evidence that support the use of botulinum toxin injections for the treatment or prevention of hypertrophic scars in current clinical practice.
A systematic review searching the MEDLINE (1966 to 2014), Scopus (2004 to 2014), Popline (1974 to 2014), ClinicalTrials.gov (2008 to 2014) and Cochrane Central Register of Controlled Trials (CENTRAL) (1999 to 2014) databases together with reference lists from included studies was conducted.
Ten studies (255 patients) were included. Of these, 123 patients were injected with botulinum toxin type A, nine patients were offered botulinum toxin type B and the remaining 123 patients represented the control groups. Significantly improved cosmetic outcomes were observed among certain studies using the visual analogue scale (experimental group: median score 8.25 [range 6 to 10]) versus control group: median score 6.38 [range 2 to 9]; P<0.001) and the Stony Brook Scar Evaluation Scale (experimental group score: 6.7 versus control group score: 4.17; P<0.001) assessments. However, the methodological heterogeneity of the included studies, the lack of control group in the majority of them, the use of subjective scales of measurement and the frequent use of patient self-assessment precluded unbiased results.
Current evidence does not support the usage of botulinum toxin. Future randomized controlled trials are needed in the field to reach firm conclusions regarding its place in current clinical practice.
在多项临床研究中,已对肉毒杆菌毒素注射用于治疗或预防增生性瘢痕进行了研究。然而,其临床有效性尚未确立。
审查当前临床实践中支持使用肉毒杆菌毒素注射治疗或预防增生性瘢痕的所有现有证据。
进行了一项系统评价,检索了MEDLINE(1966年至2014年)、Scopus(2004年至2014年)、Popline(1974年至2014年)、ClinicalTrials.gov(2008年至2014年)和Cochrane对照试验中央注册库(CENTRAL)(1999年至2014年)数据库,并纳入了研究的参考文献列表。
纳入了10项研究(255例患者)。其中,123例患者注射了A型肉毒杆菌毒素,9例患者使用了B型肉毒杆菌毒素,其余123例患者作为对照组。在某些研究中,使用视觉模拟量表(实验组:中位数评分8.25[范围6至10])与对照组(中位数评分6.38[范围2至9];P<0.001)以及石溪瘢痕评估量表(实验组评分:6.7与对照组评分:4.17;P<0.001)评估时,观察到美容效果有显著改善。然而,纳入研究的方法学异质性、大多数研究缺乏对照组、使用主观测量量表以及频繁使用患者自我评估妨碍了获得无偏结果。
目前的证据不支持使用肉毒杆菌毒素。该领域未来需要进行随机对照试验,以就其在当前临床实践中的地位得出确凿结论。